Holen Sie sich die Stockscreener-App
2.83
1.43%
0.04
Handel nachbörslich:
2.85
0.02
+0.71%
Protalix BioTherapeutics Inc. Aktie (PLX) Neueste Nachrichten
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 - Finviz
Rare-disease drug maker Protalix sets 2025 financial results call for March 18 - Stock Titan
Small cap wrap: Medicus Pharma, C3 Metals, Protalix BioTherapeutics… - Proactive Investors
European Commission Approves Once-Every-Four-Weeks Elfabrio® (Pegunigalsidase Alfa) Dosing for Fabry Disease, Reducing Treatment Burden for Adults - Minichart
EC approves new Elfabrio dosing regimen - The Pharma Letter
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen - Proactive financial news
Protalix Biotherapeutics Experiences Valuation Adjustment Amid Strong Market Performance Indicators - Markets Mojo
Chiesi Global Rare Diseases and Protalix BioTherapeutics - GlobeNewswire
Protalix Gains EU Approval for Extended Elfabrio Dosing - TipRanks
Protalix: European Commission approves 2 mg/kg every-4-weeks dosing for Elfabrio - TradingView
EU approves four-week dosing option for Chiesi and Protalix's Elfabrio - marketscreener.com
European Commission Approves New Dosing for Protalix (PLX) Elfab - GuruFocus
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) - The Manila Times
Buybacks Report: Is Protalix BioTherapeutics Inc being accumulated by smart money2025 Year in Review & Smart Investment Allocation Insights - baoquankhu1.vn
Why hedge funds are buying Protalix BioTherapeutics Inc. stockWeekly Investment Report & Momentum Based Trading Signals - Naître et grandir
Buybacks Report: Will Protalix BioTherapeutics Inc benefit from government policyJuly 2025 Big Picture & Short-Term High Return Strategies - baoquankhu1.vn
Retail Trends: Should I invest in Protalix BioTherapeutics Inc before earningsJuly 2025 Selloffs & Reliable Volume Spike Alerts - baoquankhu1.vn
MAK Capital Group (PLX) reports 4,649,599 shares, a 5.8% stake - Stock Titan
Published on: 2026-03-01 19:16:31 - baoquankhu1.vn
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Protalix BioTherapeutics Reports First Quarter 2025 Financial an - GuruFocus
PLX Should I Buy - Intellectia AI
Protalix BioTherapeutics (NYSE:PLX) Shares Down 0.7%Time to Sell? - MarketBeat
Protalix Biotherapeutics Hits New 52-Week High of $3.19 - Markets Mojo
Is Protalix BioTherapeutics Inc a top pick in the sectorTrade Ideas & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Published on: 2026-02-21 10:08:13 - baoquankhu1.vn
What is the PEG ratio of Protalix BioTherapeutics Inc.Earnings Trend Report & Safe Entry Trade Signal Reports - mfd.ru
Should I invest in Protalix BioTherapeutics Inc. before earnings2025 AllTime Highs & Risk Controlled Stock Pick Alerts - mfd.ru
Swing Trade: Will Protalix BioTherapeutics Inc benefit from rising consumer demandMarket Activity Recap & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Why Protalix BioTherapeutics Inc. stock could be next big winnerEarnings Summary Report & Safe Entry Momentum Stock Tips - mfd.ru
Shorts Report: Will Protalix BioTherapeutics Inc. (DE) stock outperform benchmarks2025 Macro Impact & Daily Risk Controlled Trade Plans - mfd.ru
Will Protalix BioTherapeutics Inc. benefit from rising consumer demandGap Down & Short-Term Trading Alerts - mfd.ru
Will Protalix BioTherapeutics Inc. benefit from government policy2025 Price Momentum & Weekly Momentum Stock Picks - mfd.ru
Protalix Highlights Positive EMA Opinion on Elfabrio Dosing - TipRanks
Protalix BioTherapeutics, Inc. Announces Positive CHMP Opinion for Elfabrio® - TradingView
Why retail investors favor Protalix BioTherapeutics Inc. stockTrade Analysis Report & Risk Adjusted Swing Trade Ideas - mfd.ru
Fabry Disease Market Hits USD 1.7 Billion in 2024, Set for Strong Expansion Across the 7MM Through 2034 | DelveInsight - Barchart.com
RSI Check: Is Protalix BioTherapeutics Inc currently under institutional pressureWeekly Market Summary & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Aug Patterns: Should I invest in Protalix BioTherapeutics Inc before earnings2025 Technical Patterns & Consistent Return Strategy Ideas - baoquankhu1.vn
Protalix Biotherapeutics Forms Golden Cross, Signaling Bullish Breakout Ahead - Markets Mojo
What is Zacks Small Cap’s Forecast for PLX FY2025 Earnings? - Defense World
Protalix BioTherapeutics (NYSE:PLX) Trading Up 6.2%Here's Why - MarketBeat
Reviewing Protalix BioTherapeutics (NYSE:PLX) & JATT Acquisition (NYSE:JATT) - Defense World
Protalix BioTherapeutics (PLX) Price Target Decreased by 12.00% to 11.22 - Nasdaq
PLX: CHMP Delivers Positive Opinion - Research Tree
Protalix says EU panel recommended a new dosing regimen for Fabry disease therapy - MSN
A March Decision That Could Change Protalix BioTherapeutics Outlook - Seeking Alpha
Protalix's New Dosing Regimen Recommended for Approval - Intellectia AI
Protalix (PLX) Surges 14% on Positive EMA Panel Opinion for Elfa - GuruFocus
Protalix rises as EU backs new dosing for Elfabrio (PLX:NYSE) - Seeking Alpha
Protalix (PLX) Gains Positive EMA Opinion for New Elfabrio Dosage - GuruFocus
Protalix Wins EMA Panel Backing for New Elfabrio Dosing - TipRanks
Protalix wins EU panel backing for expanded dosing of Fabry disease drug - Proactive financial news
Protalix BioTherapeutics Announces Positive CHMP Opinion for Elfabrio Dosing Regimen - TradingView
CHMP backs new Elfabrio regimen for Protalix (NYSE: PLX) patients - Stock Titan
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU - GlobeNewswire
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU - Yahoo Finance
Market movers: Verizon, Sandisk, Protalix Biotherapeutics, American Express… - Proactive financial news
Is Protalix BioTherapeutics Inc. a strong candidate for buy and holdJuly 2025 Retail & Weekly Return Optimization Alerts - mfd.ru
Aug Summary: Should I invest in Rentokil Initial plc Depositary Receipt before earningsJuly 2025 Movers & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Winners Losers: Can Protalix BioTherapeutics Inc sustain its profitabilityM&A Rumor & Consistent Profit Trading Strategies - baoquankhu1.vn
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):